GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks

The rising use of injectable GLP-1 weight-loss medications, which require refrigeration, is boosting demand for cold chain logistics services. FedEx, UPS, DHL Group, and C.H. Robinson are all expanding healthcare and cold-chain logistics operations to capture growing pharmaceutical shipping revenue. Each company shows distinct financials, including varying valuations, dividend yields, and revenue contributions from their healthcare logistics segments.

Many investors share the quality of being curious. That lends itself to viewing the world in a particular way and making connections that others can overlook. One of those connections is playing out in the health logistics sector, specifically in cold chain logistics. The catalyst is the GLP-1 boom, which is turning refrigerated transportation from a niche operational detail into a more important revenue opportunity for logistics companies.

According to Gallup, 11% of U.S. adults now take GLP-1 medications for weight loss purposes. That’s up from 3% in 2024. The research firm also reported that 15% of U.S. adults reported using the medicine at some point. GLP-1 pills are gaining traction, but the injectable form of the drugs is still the most common, and they must be kept refrigerated as they make their way from the manufacturer to the customer. Logistics companies already had a healthcare lever as it related to revenue. This is expanding that lever. Plus, these drugs continue to reshape food demand patterns. Users are actively seeking high-protein, nutrient-dense products that often require refrigerated storage. It’s not exactly about skating to where the puck is going, but health logistics gives investors a reason to put fresh eyes on the following companies.

Another reason to consider companies involved in health logistics is that pharmaceuticals are among the most profitable sectors for logistics companies. The stakes are high. The cost of a failed shipment is enough risk for these companies to pay a premium to ensure success. Plus, the addressable market for cold-chain pharmaceutical logistics extends beyond GLP-1 drugs to include vaccines and antibiotics.

FedEx Dividend Payments Dividend Yield 1.57% Annual Dividend $4.88 Dividend Increase Track Record 1 Year Annualized 5-Year Dividend Growth 17.12% Dividend Payout Ratio 26.36% Recent Dividend Payment Jul. 7 FDX Dividend History FedEx Corp. NYSE: FDX faces numerous headwinds across its business. However, the company’s investment in high-margin healthcare logistics is an interesting reason to consider looking for an entry point. In its fiscal year 2026, FedEx generated about $10 billion from its Healthcare Transportation vertical. While only about 10.5% of the total revenue, the number is likely to grow. That's due to the company’s launch of FedEx Life Sciences , which is focused specifically on pharmaceutical customers. As of this writing, FDX was trading within approximately 13.5% of its consensus price target of $350.54 . Plus, at around 16.6x earnings, FDX has an attractive valuation, particularly as it relates to the S&P 500. The stock also offers a modest income component, with a dividend yield near 1.6% and a payout ratio that leaves room for future increases.

UPS Doubles Down on Cold-Chain Acquisitions United Parcel Service Dividend Payments Dividend Yield 6.14% Annual Dividend $6.56 Dividend Increase Track Record 16 Years Annualized 5-Year Dividend Growth 10.18% Dividend Payout Ratio 121.93% Recent Dividend Payment Jun. 4 UPS Dividend History UPS NYSE: UPS is the other half of the perceived duopoly with...